AntiPORT: adaptation of a transfusion prediction score to an Australian cardiac surgery population

IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE
James Yeates , Lachlan Miles , Kate Blatchford , Michael Bailey , Jenni Williams-Spence , Christopher Reid , Tim Coulson
{"title":"AntiPORT: adaptation of a transfusion prediction score to an Australian cardiac surgery population","authors":"James Yeates ,&nbsp;Lachlan Miles ,&nbsp;Kate Blatchford ,&nbsp;Michael Bailey ,&nbsp;Jenni Williams-Spence ,&nbsp;Christopher Reid ,&nbsp;Tim Coulson","doi":"10.51893/2022.4.OA6","DOIUrl":null,"url":null,"abstract":"<div><p><strong>Introduction:</strong> Risk scoring systems exist to predict perioperative blood transfusion risk in cardiac surgery, but none have been validated in the Australian or New Zealand population. The ACTA-PORT score was developed in the United Kingdom for this purpose. In this study, we validate and recalibrate the ACTA-PORT score in a large national database.</p><p><strong>Methods:</strong> We performed a retrospective validation study using data from the Australian and New Zealand Society of Cardiac and Thoracic Surgeons Database between 1 September 2016 and 31 December 2018. The ACTA-PORT score was calculated using an equivalent of EuroSCORE I. Discrimination and calibration was assessed using area under the receiver operating characteristic (AUROC) curves, Brier scores, and calibration plots. ACTA-PORT was then recalibrated in a development set using logistic regression and the outcome of transfusion to develop new predicted transfusion rates, termed \"AntiPORT”, using AusSCORE \"all procedures\" as the regional equivalent of EuroSCORE I. The accuracy of these new predictions was assessed as for ACTA-PORT.</p><p><strong>Results:</strong> 30 388 patients were included in the study at 37 Australian centres. The rate of red blood cell transfusion was 33%. Discrimination of ACTA-PORT was good but calibration was poor, with overprediction of transfusion (AUROC curve, 0.76; 95% CI, 0.75-0.76; Brier score, 0.19). The recalibrated AntiPORT showed significantly improved calibration in both development and validation sets without compromising discrimination (AUROC curve, 0.76; 95% CI, 0.75-0.76; Brier score, 0.18).</p><p><strong>Conclusions:</strong> The AntiPORT is the first red cell transfusion risk scoring system for cardiac surgery patients to be validated using Australian data. It is accurate and simple to calculate. The demonstrated accuracy of AntiPORT may help facilitate benchmarking and future research in patient blood management, as well as providing a useful tool to help clinicians target these resource-saving strategies.</p></div>","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S144127722300042X/pdfft?md5=91e61d6de89e07e6bfb9e4c700cba573&pid=1-s2.0-S144127722300042X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care and Resuscitation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S144127722300042X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Risk scoring systems exist to predict perioperative blood transfusion risk in cardiac surgery, but none have been validated in the Australian or New Zealand population. The ACTA-PORT score was developed in the United Kingdom for this purpose. In this study, we validate and recalibrate the ACTA-PORT score in a large national database.

Methods: We performed a retrospective validation study using data from the Australian and New Zealand Society of Cardiac and Thoracic Surgeons Database between 1 September 2016 and 31 December 2018. The ACTA-PORT score was calculated using an equivalent of EuroSCORE I. Discrimination and calibration was assessed using area under the receiver operating characteristic (AUROC) curves, Brier scores, and calibration plots. ACTA-PORT was then recalibrated in a development set using logistic regression and the outcome of transfusion to develop new predicted transfusion rates, termed "AntiPORT”, using AusSCORE "all procedures" as the regional equivalent of EuroSCORE I. The accuracy of these new predictions was assessed as for ACTA-PORT.

Results: 30 388 patients were included in the study at 37 Australian centres. The rate of red blood cell transfusion was 33%. Discrimination of ACTA-PORT was good but calibration was poor, with overprediction of transfusion (AUROC curve, 0.76; 95% CI, 0.75-0.76; Brier score, 0.19). The recalibrated AntiPORT showed significantly improved calibration in both development and validation sets without compromising discrimination (AUROC curve, 0.76; 95% CI, 0.75-0.76; Brier score, 0.18).

Conclusions: The AntiPORT is the first red cell transfusion risk scoring system for cardiac surgery patients to be validated using Australian data. It is accurate and simple to calculate. The demonstrated accuracy of AntiPORT may help facilitate benchmarking and future research in patient blood management, as well as providing a useful tool to help clinicians target these resource-saving strategies.

AntiPORT:输血预测评分对澳大利亚心脏手术人群的适应性
风险评分系统用于预测心脏手术围手术期输血风险,但尚未在澳大利亚或新西兰人群中得到验证。ACTA-PORT评分就是为此目的在英国开发的。在这项研究中,我们在一个大型国家数据库中验证并重新校准了ACTA-PORT评分。方法:我们使用2016年9月1日至2018年12月31日期间澳大利亚和新西兰心胸外科学会数据库中的数据进行了回顾性验证研究。ACTA-PORT评分采用相当于EuroSCORE 1的方法计算。使用受试者工作特征(AUROC)曲线下的面积、Brier评分和校准图来评估鉴别和校准。然后使用逻辑回归和输血结果在开发集中重新校准ACTA-PORT,以开发新的预测输血率,称为“AntiPORT”,使用AusSCORE“所有程序”作为EuroSCORE i的区域等量物。这些新预测的准确性被评估为ACTA-PORT。结果:澳大利亚37个中心共纳入30388例患者。红细胞输注率为33%。ACTA-PORT的鉴别性较好,但校准性较差,存在输血的过度预测(AUROC曲线,0.76;95% ci, 0.75-0.76;Brier评分为0.19)。重新校准的AntiPORT在开发集和验证集上都显示出显著改善的校准,而不影响辨别(AUROC曲线,0.76;95% ci, 0.75-0.76;Brier评分0.18)。结论:AntiPORT是第一个使用澳大利亚数据验证的心脏手术患者红细胞输血风险评分系统。它是准确和简单的计算。AntiPORT所证明的准确性可能有助于促进患者血液管理的基准和未来的研究,以及提供一个有用的工具来帮助临床医生针对这些资源节约策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Critical Care and Resuscitation
Critical Care and Resuscitation CRITICAL CARE MEDICINE-
CiteScore
7.70
自引率
3.40%
发文量
44
审稿时长
>12 weeks
期刊介绍: ritical Care and Resuscitation (CC&R) is the official scientific journal of the College of Intensive Care Medicine (CICM). The Journal is a quarterly publication (ISSN 1441-2772) with original articles of scientific and clinical interest in the specialities of Critical Care, Intensive Care, Anaesthesia, Emergency Medicine and related disciplines. The Journal is received by all Fellows and trainees, along with an increasing number of subscribers from around the world. The CC&R Journal currently has an impact factor of 3.3, placing it in 8th position in world critical care journals and in first position in the world outside the USA and Europe.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信